Skip Navigation


NDT Advance Access originally published online on November 9, 2006
Nephrology Dialysis Transplantation 2007 22(1):291-293; doi:10.1093/ndt/gfl501
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/1/291    most recent
gfl501v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carroll, R. P.
Right arrow Articles by Kerr, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carroll, R. P.
Right arrow Articles by Kerr, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Anti-CD20 antibody treatment in refractory Class IV lupus nephritis

Email: doctorrobertcarroll@yahoo.com

The first 10% of the full text of this article appears below.

Sir,

Selected cases of class IV lupus nephritis patients have been treated with rituximab monotherapy [1,2] and in combination with cyclophosphamide [3]. Data on refractory patients who have failed multiple therapies are limited [4]. We have successfully treated four patients with rituximab, who have failed multiple conventional immunosuppressive regimens, including cyclophosphamide, . . . [Full Text of this Article]

Patient 1

Patient 2

Patient 3

Patient 4

Robert P. Carroll, Fiona Brown and Peter G. Kerr

Monash Medical Centre
Nephrology
Melbourne
Victoria
Australia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al.
Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome
Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22.
[Full Text] [PDF]

Home page
 LupusHome page
B. Ranchin and S. Fargue
Review: New treatment strategies for proliferative lupus nephritis: keep children in mind!
Lupus, August 1, 2007; 16(8): 684 - 691.
[Abstract] [PDF]